Clinical trial · Interventional
The Association of G9a Protein and Outcome of Patients With Endometrial Cancer
NCT01271764CI-TRIAL-00008157completedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Tumor invasion and metastasis are the major causes of cancer-related death. Some studies have found that histone methyltransferases, such as EZH2, specifically affect metastasis in breast, gastric and prostate cancer. The functional roles of other members of the HMT family such as G9a in cancer remain obscure. Therefore, the investigators will investigate whether G9a have a role in recurrence/metastasis of endometrial cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Outcome of Endometrial Cancer | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| no drug | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- NO_INTERVENTION
- label
- endometrial cancer
- interventionNames
- Other: no drug
Primary outcomes (1)
- measure
- The role of G9a protein in endometrial cancer
- timeFrame
- overall survial, disease-free survival
- description
- We will correlate the G9a protein and outcome of endometrial cancer
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 20 Years
Show eligibility criteria text
Inclusion Criteria: * all cases with endometrial cancer underwent staging operation Exclusion Criteria: * nil
References
Publications (0)
Data not yet available
No reference posted for this study.